Business
Theraclion Announces Sonovein FDA Submission Following a Strong Year of Regulatory and Clinical Achievements
MALAKOFF, France, December 09, 2025--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reports today the key regulatory and clinical communication achievements of the past year across congresses, publications, and expert presentations.
About this update from Theraclion Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":375,"url":"https://media.zenfs.com/en/business-wire.com/87b8922f6cf9d901c695268a3a1407c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BTSMw2IxIpuapqo4KRJU_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/87b8922f6cf9d901c695268a3a1407c2","width":960,"height":360},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/24HuMaZ56Qc0wdjAWYqcUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/87b8922f6cf9d901c695268a3a1407c2","width":1000,"height":375}},"lazy":false},{"type":"text","content":"MALAKOFF, France, December 09, 2025--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reports today the key regulatory and clinical communication achievements of the past year across congresses, publications, and expert presentations.","length":341,"tagName":"p"},{"type":"text","content":"Regulatory update: FDA submission","length":33,"tagName":"p"},{"type":"text","content":"Theraclion announces that the full dataset from the U.S. Food and Drug Administration pivotal study has been submitted to the FDA on schedule as part of the De Novo clearance process for Sonovein®. Based on typical FDA review timelines for comparable devices, a decision is anticipated around mid-2026. FDA clearance would authorize U.S. commercialization, giving access to the largest varicose vein treatment market.","length":417,"tagName":"p"},{"type":"text","content":"Additional regulatory progress in Europe and China","length":50,"tagName":"p"},{"type":"text","content":"In 2025, Sonovein® also achieved key regulatory milestones, including EU MDR certification and compliance with China’s GB 9706.1-2020 standard, strengthening its pathway to long-term commercialization in Europe and future market access in China.","length":245,"tagName":"p"},{"type":"text","content":"New publications and scientific evidence","length":40,"tagName":"p"},{"type":"text","content":"In 2025, several peer-reviewed publication...